Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2012

01-07-2012 | Epidemiology

Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis

Authors: Saroj Niraula, Alberto Ocana, Marguerite Ennis, Pamela J. Goodwin

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Login to get access

Abstract

Obesity is associated with poor survival after breast cancer diagnosis in individual studies and meta-analyses. Evidence regarding associations of obesity with breast cancer-specific survival (BCSS) and overall survival (OS) in relation to hormone receptor status, or BCSS in relation to menopausal status has not been evaluated in a previous meta-analysis. In this study, we conducted a meta-analysis of the association of obesity with OS and BCSS in relation to hormone receptor status and menopausal status. MEDLINE, EMBASE, and COCHRANE databases from the first record to December 2011 and presentations made at major international meetings in the last 5 years were searched. We included observational or interventional studies reporting hazard ratios (HRs) of obesity with OS and/or BCSS in relation to hormone receptor and/or menopausal status. Twenty-one studies qualified, meeting the above criteria. The pooled HR for OS in heavier versus lighter women was 1.31 (95 % CI 1.17–1.46) for estrogen receptor/progesterone receptor (ER/PgR) positive cancers; 1.18 (95 % CI 1.06–1.31) for ER/PgR negative cancers; and the difference between the two groups was not significant (p = 0.31). The pooled HR for OS in heavier versus lighter women was 1.23 (95 % CI 1.07–1.42) for premenopausal women and 1.15 (95 % CI 1.06–1.26) for post-menopausal women, and the difference between the two groups was not significant (p = 0.57). Comparable pooled HRs for BCSS were 1.36 (95 % CI 1.20–1.54) for ER/PgR positive cancers and 1.46 (95 % CI 0.98–2.19) for ER/PgR negative cancers; and 1.18 (95 % CI 0.82–1.70) for pre-menopausal women and 1.38 (95 % CI 1.11–1.71) for post-menopausal women, also without significant group differences. Results were similar after adjustment for BMI measurement technique, years of follow-up, or study design. These findings led us to conclude that there is no evidence showing that the association of obesity with breast cancer outcome differs by hormone receptor or menopausal status. This has implications for studies of weight loss interventions in the adjuvant BC setting.
Appendix
Available only for authorised users
Literature
1.
Kelly T et al (2008) Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 32(9):1431–1437CrossRef
2.
Renehan AG et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578PubMedCrossRef
3.
van den Brandt PA et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152(6):514–527PubMedCrossRef
4.
Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157–173PubMedCrossRef
5.
Goodwin P et al (1995) Development of a weight management program in women with newly diagnosed locoregional breast cancer. In: 11th international congress of psychosomatic obstetrics and gynaecology, Basel, Switzerland
6.
Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627–635PubMedCrossRef
7.
Ryu S et al (2001) Is body mass index the prognostic factor in breast cancer?: a meta-analysis. J Korean Med Sci 16(5):610–614PubMed
8.
Hursting SD et al (2008) Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract Res Clin Endocrinol Metab 22(4):659–669PubMedCrossRef
9.
Renehan AG, Roberts DL, Dive C (2008) Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 114(1):71–83PubMedCrossRef
10.
Subbaramaiah K et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 4(3):329–346CrossRef
11.
Morris PG et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4(7):1021–1029CrossRef
12.
Pfeiler G et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653–2659PubMedCrossRef
13.
Bowers L et al. (2010) Obesity promotes breast cancer progression and tamoxifen resistance via cross-talk between growth factor and estrogen signaling pathways. In: San Antonio breast cancer symposium 2010 [PD09-06]
14.
15.
Deeks J, Higgins J, Altman D (2006) Analysing and presenting results: cochrane handbook for systematic reviews of interventions 4 2 5. In: The cochrane library. John Wiley and Sons, Chichester
16.
17.
18.
van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21(4):589–624PubMedCrossRef
19.
Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1–48
20.
de Azambuja E et al (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119(1):145–153PubMedCrossRef
21.
Berclaz G et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15(6):875–884PubMedCrossRef
22.
Conroy SM et al (2011) Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res Treat 129(2):565–574PubMedCrossRef
23.
Chang S et al (2000) Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64(2):157–163PubMedCrossRef
24.
Chen X et al (2010) Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat 122(3):823–833PubMedCrossRef
25.
Dal Maso L et al (2008) Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer 123(9):2188–2194PubMedCrossRef
26.
Dignam JJ et al (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476PubMedCrossRef
27.
Dignam JJ et al (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97(3):245–254PubMedCrossRef
28.
Daling JR et al (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 92(4):720–729PubMedCrossRef
29.
Enger SM, Bernstein L (2004) Exercise activity, body size and premenopausal breast cancer survival. Br J Cancer 90(11):2138–2141PubMed
30.
Goodwin PJ et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51PubMedCrossRef
31.
Keegan THM et al (2010) Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry. Breast Cancer Res Treat 123(2):531–542PubMedCrossRef
32.
Kwan ML et al. (2011) Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Research & Treatment
33.
Loi S et al (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14(7):1686–1691PubMedCrossRef
34.
Majed B et al (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111(2):329–342PubMedCrossRef
35.
Vitolins MZ, Kimmick GG, Case LD (2008) BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer. Breast J 14(4):357–365PubMedCrossRef
36.
Whiteman MK et al (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 14(8):2009–2014PubMedCrossRef
37.
Sparano JA et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671PubMedCrossRef
38.
Davidson NE et al (2005) Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23(25):5973–5982PubMedCrossRef
39.
Fetting JH et al (1998) Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol 16(7):2382–2391PubMed
40.
Sparano J et al. (2010) Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer. In: San Antonio breast cancer symphosium 2010 [S2-1]
41.
Sestak I et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415PubMedCrossRef
42.
den Tonkelaar I, Seidell JC, Collette HJ (1995) Body fat distribution in relation to breast cancer in women participating in the DOM-project. Breast Cancer Res Treat 34(1):55–61CrossRef
43.
Demirkan B, Alacacioglu A, Yilmaz U (2007) Relation of body mass index (BMI) to disease free (DFS) and distant disease free survivals (DDFS) among Turkish women with operable breast carcinoma. Jpn J Clin Oncol 37(4):256–265PubMedCrossRef
44.
Maehle BO, Tretli S (1996) Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat 41(2):123–130PubMedCrossRef
45.
Mohle-Boetani JC et al (1988) Body size, reproductive factors, and breast cancer survival. Prev Med 17(5):634–642PubMedCrossRef
46.
Lu Y et al (2011) Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 29(25):3358–3365PubMedCrossRef
47.
Jain MG et al (2005) Body mass index and mortality in women: follow-up of the Canadian National Breast Screening Study cohort. Int J Obes 29(7):792–797CrossRef
48.
Kroenke CH et al (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23(7):1370–1378PubMedCrossRef
49.
den Tonkelaar I et al (1995) Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project. Breast Cancer Res Treat 34(2):129–137CrossRef
50.
Abrahamson PE et al (2006) General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev 15(10):1871–1877PubMedCrossRef
51.
Barnett GC et al (2008) Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 26(20):3310–3316PubMedCrossRef
52.
Bastarrachea J et al (1994) Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120(1):18–25PubMed
53.
Borugian MJ et al (2003) Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol 158(10):963–968PubMedCrossRef
54.
Caan BJ et al (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19(10):1319–1328PubMedCrossRef
55.
Carmichael AR et al (2004) Does obesity compromise survival in women with breast cancer? Breast 13(2):93–96PubMedCrossRef
56.
Cleveland RJ et al (2007) Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev 16(9):1803–1811PubMedCrossRef
57.
Dawood S et al (2008) Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res 14(6):1718–1725PubMedCrossRef
58.
Eley JW et al (1994) Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 272(12):947–954PubMedCrossRef
59.
Greenberg ER et al (1985) Body size and survival in premenopausal breast cancer. Br J Cancer 51(5):691–697PubMedCrossRef
60.
Hebert JR, Hurley TG, Ma Y (1998) The effect of dietary exposures on recurrence and mortality in early stage breast cancer. Breast Cancer Res Treat 51(1):17–28PubMedCrossRef
61.
Holmberg L et al (1994) Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 30A(3):351–354PubMedCrossRef
62.
Katoh A, Watzlaf VJ, D’Amico F (1994) An examination of obesity and breast cancer survival in post-menopausal women. Br J Cancer 70(5):928–933PubMedCrossRef
63.
Labidi SI et al (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19(3):473–480PubMedCrossRef
64.
Litton JK et al (2008) Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072–4077PubMedCrossRef
65.
Mason BH et al (1990) Season of tumour detection influences factors predicting survival of patients with breast cancer. Breast Cancer Res Treat 15(1):27–37PubMedCrossRef
66.
Moon HG, Han W, Noh DY (2009) Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J Clin Oncol 27(35):5899–5905PubMedCrossRef
67.
Newman SC, Lees AW, Jenkins HJ (1997) The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol 26(3):484–490PubMedCrossRef
68.
Nichols HB et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18(5):1403–1409PubMedCrossRef
69.
Petrelli JM et al (2002) Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13(4):325–332PubMedCrossRef
70.
Pierce JP et al (2007) Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 25(17):2345–2351PubMedCrossRef
71.
Reeves GK et al (2000) Hormonal and other factors in relation to survival among breast cancer patients. Int J Cancer 89(3):293–299PubMedCrossRef
72.
Rosenberg L, Czene K, Hall P (2009) Obesity and poor breast cancer prognosis: an illusion because of hormone replacement therapy? Br J Cancer 100(9):1486–1491PubMedCrossRef
73.
Saxe GA et al (1999) Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat 53(3):241–253PubMedCrossRef
74.
Tao MH et al (2006) Association of overweight with breast cancer survival. Am J Epidemiol 163(2):101–107PubMedCrossRef
75.
Vatten LJ, Foss OP, Kvinnsland S (1991) Overall survival of breast cancer patients in relation to preclinically determined total serum cholesterol, body mass index, height and cigarette smoking: a population-based study. Eur J Cancer 27(5):641–646PubMedCrossRef
76.
Chlebowski RT et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98(24):1767–1776PubMedCrossRef
77.
Rock CL et al (2008) Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomark Prev 17(3):614–620CrossRef
78.
Mulligan AM et al (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106(1):39–47PubMedCrossRef
79.
Law JH et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24):10238–10246PubMedCrossRef
80.
Goodwin PJ et al (2005) Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 23(25):6037–6042PubMedCrossRef
81.
Duggan C et al (2011) Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29(1):32–39PubMedCrossRef
82.
Emaus A et al (2010) Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat 121(3):651–660PubMedCrossRef
83.
Erickson K et al (2011) Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 29(1):54–60PubMedCrossRef
84.
Irwin ML et al (2011) Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 29(1):47–53PubMedCrossRef
85.
Ma J et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047PubMedCrossRef
86.
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928PubMedCrossRef
87.
Doyle SL et al (2011) Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 1–9
88.
Goodwin PJ et al (2011) Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol
89.
Egger M, Schneider M, Davey Smith G (1998) Spurious precision? Meta-analysis of observational studies. BMJ 316(7125):140–144PubMedCrossRef
90.
Thivat E et al (2010) Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer 10:648PubMedCrossRef
91.
Chauvet B et al (1990) Prognostic significance of breast relapse after conservative treatment in node-negative early breast cancer. Int J Radiat Oncol Biol Phys 19(5):1125–1130PubMedCrossRef
92.
Marret H et al (2001) Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer. Breast Cancer Res Treat 66(1):17–23PubMedCrossRef
Metadata
Title
Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis
Authors
Saroj Niraula
Alberto Ocana
Marguerite Ennis
Pamela J. Goodwin
Publication date
01-07-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2073-x

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue

Letter to the Editor

High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?

Preclinical Study

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

Clinical Trial

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

Epidemiology

The economic burden of metastatic breast cancer: a U.S. managed care perspective

Preclinical Study

Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells

Preclinical Study

Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits